RE:RE:RE:RE:RE:RE:RE:RE:New base $2 Read the presentation reddy. The insulin reduction on the one reported patient isn't that much and not significant. Only the quick acting insulin but that could be reduced by dietary changes as the patient has also lost significant weight.
Redbaron2211 wrote: Agree. As we hone in dosing, the amount of top up needed should be less, and it's important to note insulin production before top up is already significant. With cells surviving long term and the pouch showing safety and efficacy in multiple patients, this is without a doubt the best option for multiple indications. We already know this tech was reaching 1B+ valuations preclinical. If the data continues to show clinical success in multiple patients, there is no reason we should be sitting at less than 1B US and multiple billions if we see a deal with steps being taken towards immune protection. As this is de-risked with multiple patients, institutional buying become more likely to help with a re-rate.